Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Dénes Csonka"'
Autor:
Dénes Csonka, Vladislav Fishman, Jaya Natarajan, Hans Stieltjes, Danielle Armas, Victor Dishy, Juan Jose Perez Ruixo
Publikováno v:
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Abstract The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned. Thus, the aim was to demonstrate bioequivalence, using an adaptive study design
Externí odkaz:
https://doaj.org/article/31a919ca32f146339e7cacbab7365ba6
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Abstract To compare the pharmacokinetic (PK) properties of the pediatric dispersible tablet formulation of macitentan and the adult film‐coated tablet formulation of macitentan in healthy subjects. A randomized, open‐label, single‐dose, two‐s
Externí odkaz:
https://doaj.org/article/3b790bd2f12d45a28256fdd316cd810a
Autor:
Patricia N. Sidharta, Shirin Bruderer, Susanne Globig, James Carlson, Dénes Csonka, Mariya Antonova, Simon Grill, Armin Schultz
Publikováno v:
British Journal of Clinical Pharmacology
Aims To demonstrate the bioequivalence of macitentan/tadalafil fixed-dose combination (FDC) tablets with single-component tablets of macitentan and tadalafil in healthy subjects. Methods Studies AC-077-101 and AC-077-103 were single-centre, open-labe
Autor:
Juan Jose Perez-Ruixo, Paolo Magni, Roberta Bartolucci, Dénes Csonka, Anne-Gaëlle Dosne, Italo Poggesi
Publikováno v:
Clinical pharmacokinetics. 60(12)
Macitentan and its active metabolite, aprocitentan, are non-peptide, potent, dual endothelin receptor antagonists. Macitentan is approved for the treatment of pulmonary arterial hypertension in adults, at a dose of 10 mg/day. The objective of this st
Autor:
Danielle Armas, Vladislav Fishman, Victor Dishy, Juan Jose Perez Ruixo, Jaya Natarajan, Dénes Csonka, Hans Stieltjes
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
Pharmacology Research & Perspectives, Vol 9, Iss 5, Pp n/a-n/a (2021)
The COVID‐19 pandemic has forced clinical studies to accommodate imposed limitations. In this study, the bioequivalence part could not be conducted as planned. Thus, the aim was to demonstrate bioequivalence, using an adaptive study design, of tada
Autor:
Radka Stepanova, Armin Schultz, Giancarlo Sabattini, Shirin Bruderer, Dénes Csonka, Juan Jose Perez-Ruixo, Marianne Soergel
Publikováno v:
Clinical Drug Investigation
Background Macitentan is a clinically approved endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH). Increasing use of combination drug therapy in PAH means that it is important to recognize potential drug–drug
Autor:
Jennifer Lynn Ford, Ahad Sabet, Jaya Natarajan, Hans Stieltjes, Daniel L. Chao, Navin Goyal, Denes Csonka
Publikováno v:
Pharmacology Research & Perspectives, Vol 12, Iss 3, Pp n/a-n/a (2024)
Abstract The primary aim was to demonstrate bioequivalence between the 10/20 mg fixed‐dose combination (FDC) of macitentan/tadalafil in a single tablet and the free combination of both drugs, and to evaluate the food effect on the 10/20 mg FDC in h
Externí odkaz:
https://doaj.org/article/9f9481ba906943d08acf091610bbda6a
Publikováno v:
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
Pharmacology Research & Perspectives, Vol 8, Iss 2, Pp n/a-n/a (2020)
To compare the pharmacokinetic (PK) properties of the pediatric dispersible tablet formulation of macitentan and the adult film‐coated tablet formulation of macitentan in healthy subjects. A randomized, open‐label, single‐dose, two‐sequence,
Autor:
Nicolas Martin, Dénes Csonka, Marius M. Hoeper, Nick H. Kim, Michael J. Krowka, Emmanuelle Cottreel, Laurent Savale, Olivier Sitbon, Pascal de Groote, Jaume Bosch
Publikováno v:
Lancet Respiratory medicine
Lancet Respiratory medicine, Elsevier, 2019, 7, pp.594-604. ⟨10.1016/S2213-2600(19)30091-8⟩
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine, 2019, 7, pp.594-604. ⟨10.1016/S2213-2600(19)30091-8⟩
Lancet Respiratory medicine, Elsevier, 2019, 7, pp.594-604. ⟨10.1016/S2213-2600(19)30091-8⟩
The Lancet Respiratory Medicine
The Lancet Respiratory Medicine, 2019, 7, pp.594-604. ⟨10.1016/S2213-2600(19)30091-8⟩
No dedicated randomised clinical trials have evaluated therapies for pulmonary arterial hypertension in patients with portopulmonary hypertension. The endothelin receptor antagonist macitentan has demonstrated long-term efficacy in pulmonary arterial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f559e27a73f8205d5b3cbf6e6a23ee6
https://hal.archives-ouvertes.fr/hal-03486263/file/S2213260019300918.pdf
https://hal.archives-ouvertes.fr/hal-03486263/file/S2213260019300918.pdf
Publikováno v:
C51. CLOSER TO THE HEART: UPDATE ON APPROVED THERAPIES FOR PAH.